Search

Your search keyword '"Wijatyk, Anna"' showing total 28 results
Start Over Author "Wijatyk, Anna"
28 results on '"Wijatyk, Anna"'

1. P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY

Author

Shah, Nirav, primary, Maziarz, Richard, additional, Jacobson, Caron, additional, Isufi, Iris, additional, Ghosh, Monalisa, additional, Ulrickson, Matthew, additional, Perales, Miguel-Angel, additional, Lunning, Matthew, additional, Hardy, Nancy, additional, Wijatyk, Anna, additional, Ancukiewicz, Marek, additional, Nallewar, Madhavi, additional, Coleman, Kimberly, additional, Prudner, Bethany, additional, Eromosele, Esther, additional, Kaleta, Remigiusz, additional, and Miklos, David, additional

Published
2023
Full Text
View/download PDF

2. Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa

Author

Goker-Alpan, Ozlem, Nedd, Khan, Shankar, Suma P., Lien, Yeong-Hau H., Weinreb, Neal, Wijatyk, Anna, Chang, Peter, Martin, Rick, Zschocke, Johannes, Editor-in-chief, Baumgartner, Matthias, editor, Morava, Eva, editor, Patterson, Marc, editor, Rahman, Shamima, editor, and Peters, Verena, editor

Published
2015
Full Text
View/download PDF

3. Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy: Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/ Refractory (R/R) DLBCL (DALY II USA NCT04792489)

Author

Shah, Nirav N., primary, Maziarz, Richard T, additional, Jacobson, Caron A., additional, Ghosh, Monalisa, additional, Isufi, Iris, additional, Ulrickson, Matthew L., additional, Perales, Miguel-Angel, additional, Lunning, Matthew, additional, Hardy, Dr. Nancy Maureen, additional, Wijatyk, Anna, additional, Ancukiewicz, Marek, additional, Nallewar, Mrs. Madhavi, additional, Coleman, Kimberly C., additional, Prudner, Bethany, additional, Eromosele, Esther, additional, Kaleta, Remi, additional, and Miklos, David B., additional

Published
2023
Full Text
View/download PDF

5. Abstract 1677: Characterization of the pharmacodynamic activity of AGEN1181, an Fc-enhanced CTLA-4 antibody, alone and in combination with the PD-1 antibody balstilimab

Author

Shapiro, Irina, primary, Lim, Min, additional, Pabla, Simarjot, additional, O'Day, Steven J., additional, El-Khoueiry, Anthony, additional, Ramamurthy, Chethan, additional, Bullock, Andrea J., additional, Gordon, Michael S., additional, Buell, Jennifer, additional, Chand, Dhan, additional, and Wijatyk, Anna, additional

Published
2021
Full Text
View/download PDF

6. 267 Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer

Author

O’Malley, David, primary, Feliu, Waldo Ortuzar, additional, Ray-Coquard, Isabelle, additional, O’Neal, Michael, additional, Alexandre, Jerome, additional, Cole, Julie, additional, Ludwig, Robert, additional, Nallewar, Madhavi, additional, Buell, Jennifer, additional, Kaleta, Remigiusz, additional, Wijatyk, Anna, additional, and Borisovskaya, Victoria, additional

Published
2020
Full Text
View/download PDF

7. 377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

Author

Galand, Claire, primary, Venkatraman, Vignesh, additional, Marques, Marilyn, additional, Strauss, James, additional, Carvajal, Richard, additional, Lim, Min, additional, Morin, Benjamin, additional, Ignatovich, Olga, additional, Findeis, Mark, additional, Underwood, Dennis, additional, Dijk, Marc Van, additional, Shapiro, Irina, additional, Ohanjanian, Lernik, additional, Wijatyk, Anna, additional, Wilson, Nicholas, additional, Buell, Jennifer, additional, Chand, Dhan, additional, Savitsky, David, additional, and Tolcher, Anthony, additional

Published
2020
Full Text
View/download PDF

9. 16 - Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy: Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/ Refractory (R/R) DLBCL (DALY II USA NCT04792489)

Author

Shah, Nirav N., Maziarz, Richard T, Jacobson, Caron A., Ghosh, Monalisa, Isufi, Iris, Ulrickson, Matthew L., Perales, Miguel-Angel, Lunning, Matthew, Hardy, Dr. Nancy Maureen, Wijatyk, Anna, Ancukiewicz, Marek, Nallewar, Mrs. Madhavi, Coleman, Kimberly C., Prudner, Bethany, Eromosele, Esther, Kaleta, Remi, and Miklos, David B.

Published
2023
Full Text
View/download PDF

10. AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment of patients with advanced malignancies.

Author

O'Day, Steven, primary, Ramamurthy, Chethan, additional, Bullock, Andrea J., additional, El-Khoueiry, Anthony B., additional, Ohanjanian, Lernik, additional, Wijatyk, Anna, additional, Ortuzar Feliu, Waldo Ignacio, additional, Shapiro, Irina, additional, Ancukiewicz, Marek, additional, Chand, Dhan, additional, Buell, Jennifer, additional, and Gordon, Michael S., additional

Published
2020
Full Text
View/download PDF

11. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Maertens, Johan, Cordonnier, Catherine, Jaksch, Peter, Poire, Xavier, Uknis, Marc, Wu, Jingyang, Wijatyk, Anna, Saliba, Faouzi, Witzke, Oliver, Villano, Stephen, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Maertens, Johan, Cordonnier, Catherine, Jaksch, Peter, Poire, Xavier, Uknis, Marc, Wu, Jingyang, Wijatyk, Anna, Saliba, Faouzi, Witzke, Oliver, and Villano, Stephen

Abstract

BACKGROUND: Maribavir is a benzimidazole riboside with activity against cytomegalovirus (CMV). The safety and efficacy of maribavir for preemptive treatment of CMV infection in transplant recipients is not known. METHODS: In a phase 2, open-label, maribavir dose-blinded trial, recipients of hematopoietic-cell or solid-organ transplants (≥18 years of age, with CMV reactivation [1000 to 100,000 DNA copies per milliliter]) were randomly assigned to receive maribavir at a dose of 400, 800, or 1200 mg twice daily or the standard dose of valganciclovir for no more than 12 weeks. The primary efficacy end point was the percentage of patients with a response to treatment, defined as confirmed undetectable CMV DNA in plasma, within 3 weeks and 6 weeks after the start of treatment. The primary safety end point was the incidence of adverse events that occurred or worsened during treatment. RESULTS: Of the 161 patients who underwent randomization, 159 received treatment, and 156 had postbaseline data available - 117 in the maribavir group and 39 in the valganciclovir group. The percentage of patients with postbaseline data available who had a response to treatment within 3 weeks was 62% among those who received maribavir and 56% among those who received valganciclovir. Within 6 weeks, 79% and 67% of patients, respectively, had a response (risk ratio, 1.20; 95% confidence interval, 0.95 to 1.51). The percentages of patients with a response to treatment were similar among the maribavir dose groups. Two patients who had a response to treatment had a recurrence of CMV infection within 6 weeks after starting maribavir at a dose of 800 mg twice daily; T409M resistance mutations in CMV UL97 protein kinase developed in both patients. The incidence of serious adverse events that occurred or worsened during treatment was higher in the maribavir group than in the valganciclovir group (52 of 119 patients [44%] vs. 13 of 40 [32%]). A greater percentage of patients in the maribavir group disc

Published
2019

13. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

Author

Beck, Michael, Hughes, Derralynn, Kampmann, Christoph, Larroque, Sylvain, Mehta, Atul, Pintos-Morellell, Guillem, Ramaswami, Uma, West, Michael, Wijatyk, Anna, Giugliani, Roberto, and Universitat Autònoma de Barcelona

Subjects
medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Urology, Cardiomyopathy, Renal function, SE, Standard error, Left ventricular hypertrophy, Biochemistry, LVH, Left ventricular hypertrophy, Long-term effectiveness, Endocrinology, Genetics, Medicine, MDRD, Modification of Diet in Renal Disease, lcsh:QH301-705.5, Molecular Biology, Agalsidase alfa, eGFR, Estimated glomerular filtration rate, Fabry disease, lcsh:R5-920, CI, Confidence interval, business.industry, Enzyme replacement therapy, medicine.disease, Egfr, Estimated glomerular filtration rate, Surgery, ARB, Angiotensin receptor blocker, SEM, Standard error of the mean, Standard error, lcsh:Biology (General), SI:Therapy, Cohort, FOS, Fabry Outcome Survey, LVMI, Left ventricular mass indexed to height, lcsh:Medicine (General), business, ACEI, Angiotensin-converting enzyme inhibitor, ERT, Enzyme replacement therapy
Abstract

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no treatment, patients treated with agalsidase alfa demonstrated slower decline in renal function and slower progression of left ventricular hypertrophy. Treated male patients with baseline eGFR < 60 mL/min/1.73 m 2 had a mean (standard error of the mean [SEM]) annualized change in eGFR of − 2.86 (0.53) mL/min/1.73 m 2 /y compared with − 6.8 (1.5) in the published untreated cohort. The mean (SEM) rate of LVMI increase with treatment was 0.33 (0.10) g/m 2.7 /y in males and 0.48 (0.09) in females, compared with 4.07 (1.03) in untreated males and 2.31 (0.81) in untreated females. Morbidity occurred later in treated patients, with ~ 16% risk of a composite morbidity event (26% in males) after 24 months with ERT versus ~ 45% without treatment, with first events and deaths also occurring at older ages in patients administered ERT (e.g., estimated median survival in treated males was 77.5 years versus 60 years in untreated males). Findings from these retrospective comparisons of observational data and published literature support the long-term benefits of ERT with agalsidase alfa for Fabry disease in slowing the progression of renal impairment and cardiomyopathy. Treatment also appeared to delay the onset of morbidity and mortality. Interpretation of these findings should take into account that they are based on retrospective comparisons with previously published data.

Published
2015

14. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

Author

Papanicolaou, Genovefa A, primary, Silveira, Fernanda P, additional, Langston, Amelia A, additional, Pereira, Marcus R, additional, Avery, Robin K, additional, Uknis, Marc, additional, Wijatyk, Anna, additional, Wu, Jingyang, additional, Boeckh, Michael, additional, Marty, Francisco M, additional, and Villano, Stephen, additional

Published
2018
Full Text
View/download PDF

15. Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study

Author

Papanicolaou, Genovefa A., primary, Silveira, Fernanda P., additional, Langston, Amelia A., additional, Pereira, Marcus R., additional, Avery, Robin K., additional, Wijatyk, Anna, additional, Wu, Jingyang J., additional, Boeckh, Michael J., additional, Marty, Francisco M., additional, and Villano, Stephen, additional

Published
2017
Full Text
View/download PDF

16. Maribavir Versus Valganciclovir for Pre-Emptive Treatment of Cytomegalovirus Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients

Author

Maertens, Johan A., primary, Cordonnier, Catherine, additional, Jaksch, Peter, additional, Poiré, Xavier, additional, Wu, Jingyang J., additional, Wijatyk, Anna, additional, Saliba, Faouzi, additional, Witzke, Oliver, additional, and Villano, Stephen, additional

Published
2017
Full Text
View/download PDF

17. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.

Author

Papanicolaou, Genovefa A, Silveira, Fernanda P, Langston, Amelia A, Pereira, Marcus R, Avery, Robin K, Uknis, Marc, Wijatyk, Anna, Wu, Jingyang, Boeckh, Michael, Marty, Francisco M, and Villano, Stephen

Subjects
ANTIVIRAL agents, CYTOMEGALOVIRUS diseases, DNA, DRUG resistance, HEMATOPOIETIC stem cell transplantation, GENETIC mutation, NEUTROPHILS, NUCLEOSIDES, TASTE disorders, TIME, TRANSPLANTATION of organs, tissues, etc., RANDOMIZED controlled trials, TREATMENT effectiveness, ADVERSE health care events, DESCRIPTIVE statistics, THERAPEUTICS
Abstract

Background Cytomegalovirus (CMV) infections that are refractory or resistant (RR) to available antivirals ([val]ganciclovir, foscarnet, cidofovir) are associated with higher mortality in transplant patients. Maribavir is active against RR CMV strains. Methods Hematopoietic-cell or solid-organ transplant recipients ≥12 years old with RR CMV infections and plasma CMV deoxyribonucleic acid (DNA) ≥1000 copies/mL were randomized (1:1:1) to twice-daily dose-blinded maribavir 400, 800, or 1200 mg for up to 24 weeks. The primary efficacy endpoint was the proportion of patients with confirmed undetectable plasma CMV DNA within 6 weeks of treatment. Safety analyses included the frequency and severity of treatment-emergent adverse events (TEAEs). Results From July 2012 to December 2014, 120 patients were randomized and treated (40 per dose group): 80/120 (67%) patients achieved undetectable CMV DNA within 6 weeks of treatment (95% confidence interval, 57–75%), with rates of 70%, 63%, and 68%, respectively, for maribavir 400, 800, and 1200 mg twice daily. Recurrent on-treatment CMV infections occurred in 25 patients; 13 developed mutations conferring maribavir resistance. Maribavir was discontinued due to adverse events in 41/120 (34%) patients, and 17/41 discontinued due to CMV infections. During the study, 32 (27%) patients died, 4 due to CMV disease. Dysgeusia was the most common TEAE (78/120; 65%) and led to maribavir discontinuation in 1 patient. Absolute neutrophil counts <1000/µL were noted in 12/106 (11%) evaluable patients, with rates similar across doses. Conclusions Maribavir ≥400 mg twice daily was active against RR CMV infections in transplant recipients; no new safety signals were identified. Clinical Trials Registration NCT01611974. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

19. Maribavir for Treatment of Cytomegalovirus (CMV) Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant (SCT) or Solid Organ Transplant (SOT) Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study

Author

Papanicolaou, Genovefa, primary, Silveira, Fernanda P., additional, Langston, Amelia, additional, Pereira, Marcus R., additional, Avery, Robin, additional, Wijatyk, Anna, additional, Wu, Jingyang J, additional, Boeckh, Michael, additional, Marty, Francisco M., additional, and Villano, Stephen, additional

Published
2016
Full Text
View/download PDF

20. Maribavir Versus Valganciclovir for Preemptive Treatment of Cytomegalovirus (CMV) Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant (SCT) and Solid Organ Transplant (SOT) Recipients

Author

Maertens, Johan, primary, Cordonnier, Catherine, additional, Jaksch, Peter, additional, Poiré, Xavier, additional, Wu, Jingyang J, additional, Wijatyk, Anna, additional, Saliba, Faouzi, additional, Witzke, Oliver, additional, and Villano, Stephen, additional

Published
2016
Full Text
View/download PDF

21. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

Author

Goláň,Lubor, Goker-Alpan,Ozlem, Holida,Myrl, Kantola,Ikka, Klopotowski,Mariusz, Kuusisto,Johanna, Linhart,Aleš, Musial,Jacek, Nicholls,Kathleen, Gonzalez-Rodríguez,Derlis, Sharma,Reena, Vujkovac,Bojan, Chang,Peter, Wijatyk,Anna, Goláň,Lubor, Goker-Alpan,Ozlem, Holida,Myrl, Kantola,Ikka, Klopotowski,Mariusz, Kuusisto,Johanna, Linhart,Aleš, Musial,Jacek, Nicholls,Kathleen, Gonzalez-Rodríguez,Derlis, Sharma,Reena, Vujkovac,Bojan, Chang,Peter, and Wijatyk,Anna

Abstract

Lubor Goláň,1 Ozlem Goker-Alpan,2 Myrl Holida,3 Ikka Kantola,4 Mariusz Klopotowski,5 Johanna Kuusisto,6 Aleš Linhart,1 Jacek Musial,7 Kathleen Nicholls,8 Derlis Gonzalez-Rodriguez,9 Reena Sharma,10 Bojan Vujkovac,11 Peter Chang,12 Anna Wijatyk12 1First Faculty of Medicine, Department of Cardiovascular Medicine, Charles University, Prague, Czech Republic; 2Lysosomal Research and Treatment Unit, Fairfax, VA, USA; 3Stead Family Department of Pediatrics, Division of Medical Genetics, University of Iowa Hospitals and Clinics, Iowa City, IA, USA; 4Division of Medicine, Turku University Hospital, Turku, Finland; 5Institute of Cardiology, Warsaw, Poland; 6Department of Medicine, Center for Medicine and Clinical Research, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland; 7Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland; 8Department of Nephrology, Royal Melbourne Hospital and the University of Melbourne, VIC, Australia; 9Instituto Privado de Hematologia E Investigacion Clinica (IPHIC), Asuncion, Paraguay; 10Salford Royal NHS Foundation Trust, Salford, UK; 11General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia; 12Shire, Lexington, MA, USA Purpose: Efficacy and safety of agalsidase alfa at 0.2 mg/kg weekly were compared with 0.2 mg/kg every other week (EOW). Exploratory analyses were performed for 0.4 mg/kg weekly.Patients and methods: This was a 53-week, Phase III/IV, multicenter, open-label study (NCT01124643) in treatment-naïve adults (≥18 years) with Fabry disease. Inclusion criteria were left ventricular hypertrophy at baseline, defined as left ventricular mass indexed to height >50 g/m2.7 for males and >47 g/m2.7 for females. Primary endpoint was reduction of left ventricular mass indexed to height as assessed by echocardiography. Secondary endpoints included cardiac (peak oxygen cons

Published
2015

22. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

Author

Goláň, Lubor, primary, Goker-Alpan, Ozlem, additional, Holida, Myrl, additional, Kantola, Ikka, additional, Klopotowski, Mariusz, additional, Kuusisto, Johanna, additional, Linhart, Aleš, additional, Musial, Jacek, additional, Nicholls, Kathleen, additional, Gonzalez Rodríguez, Derlis, additional, Sharma, Reena, additional, Vujkovac, Bojan, additional, Chang, Peter, additional, and Wijatyk, Anna, additional

Published
2015
Full Text
View/download PDF

26. Agalsidase alfa in pediatric patients with Fabry disease: A 7-year open-label study

Author

Chang Peter, Wijatyk Anna, Gregory M. Pastores, Martin Rick, and Raphael Schiffmann

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, medicine.disease, Biochemistry, Fabry disease, Endocrinology, Open label study, Genetics, Medicine, business, Molecular Biology, Agalsidase alfa
Published
2013

28. An efficient method for the synthesis of 6,7-bis(alkylthio-or alkylamino-substituted) quinoline-5,8-diones via nucleophilic addition/oxidation of alkylthio and alkylamino derivatives to quinoline-5,8-dione.

Author

Odens, Herman H., Silva, Trevor S., Olusola, Candace N., Odens Jr., Herman H., Howe, Victoria A., and Wijatyk, Anna I.

Subjects
*CHEMICAL synthesis, *GROUP rings, *OXIDATION, *ACETONITRILE, *NUCLEOPHILES
Abstract

A new variety of 6,7-bis(alkylthio-or alkylamino-substituted)quinoline-5,8-diones were prepared by the addition of mercaptans or amino nucleophiles to quinoline-5,8-dione after subsequent oxidation with NaIO4. The core quinoline-5,8-dione intermediate was prepared from the oxidation of 5-quinolinol or 8-quinolinol by [bis(trifluoroacetoxy)iodo]benzene, PIFA, in the presence of water and acetonitrile as solvents. No good leaving groups were utilized to insert the alkylthio or alkylamino groups into the quinoline ring. The synthesized compounds will be tested for their anti-inflammatory, anti-bacterial and tuberculostatic inhibition activities at a later stage. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results